Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1

Conditions

Breast Neoplasms 361Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Lymphoma 297Leukemia 254Multiple Myeloma 246Leukemia, Myeloid, Acute 241Lymphoma, Non-Hodgkin 240Lymphoma, Large B-Cell, Diffuse 238Leukemia, Lymphocytic, Chronic, B-Cell 220Myelodysplastic Syndromes 184Lymphoma, Follicular 176Hodgkin Disease 165Lymphoma, Mantle-Cell 163Burkitt Lymphoma 160Lymphoma, B-Cell, Marginal Zone 117Recurrence 115Lymphoma, Large-Cell, Immunoblastic 95Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Myeloproliferative Disorders 81Melanoma 78Neoplasms, Plasma Cell 77Leukemia, Myeloid, Chronic-Phase 72Hematologic Neoplasms 72Leukemia, Myeloid, Accelerated Phase 71Leukemia, Myelomonocytic, Chronic 69Lymphoma, B-Cell 65Dendritic Cell Sarcoma, Interdigitating 64Triple Negative Breast Neoplasms 63Ovarian Neoplasms 61Congenital Abnormalities 59

Interventions

eribulin 3Vinorelbine 2Paclitaxel 2Epirubicin 2Doxorubicin 2Cyclophosphamide 2trastuzumab deruxtecan 1tislelizumab 1taxane 1sacituzumab govitecan 1pembrolizumab 1liposomal doxorubicin 1camrelizumab 1anlotinib 1Taxes 1Precision Medicine 1Gemcitabine 1Docetaxel 1Cisplatin 1Carboplatin 1Capecitabine 1Anthracyclines 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HER2-negative Breast Cancer × Cyclophosphamide × Clear all
NCT05275777 2025-07-25

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

National University Hospital, Singapore

Phase 1/2 Active not recruiting
66 enrolled
BreastOther solid neoplasm

HER2-negative Breast Cancer

NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Recruiting
260 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡